Compare Live Nation Entertainment, Inc. (LYV) vs Novavax Inc (NVAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Live Nation Entertainment, Inc. vs Novavax Inc — how do they compare? Live Nation Entertainment, Inc. trades at $170.33 (market cap $39.92B), while Novavax Inc trades at $12.75 (market cap $1.82B). The key difference: Live Nation Entertainment, Inc. is far larger — about 21.9× Novavax Inc's market cap, and Novavax Inc is trading nearer its 52-week high, Live Nation Entertainment, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Live Nation Entertainment, Inc. for 72 Days and Novavax Inc for 59 Days on average.
| LYV | NVAX | |
|---|---|---|
Market Cap | $39.92B | $1.82B |
Volume | 1,982,609 | 6,198,505 |
Sector | Media | Health |
52-Week High | $188.46 | $12.75 |
52-Week Low | $125.61 | $6.22 |
Typical Hold Time | 72 Days | 59 Days |
Enterprise Value | $42.13B | $1.39B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Live Nation Entertainment (LYV) trades at $171.34, up 0.29% with a bullish technical signal and strong analyst support. The company reported mixed Q2 2026 earnings with a beat on EPS but faces valuation concerns with a P/E of 117.49 and negative ROE of -116.65%. Recent news highlights strong consumer demand for live events and strategic partnerships, though insider selling and regulatory scrutiny present headwinds.
The outlook remains positive with 87% analyst buy ratings and a $208.18 price target, representing 21% upside. Key risks include high debt levels, margin pressure, and ongoing regulatory challenges. Revenue growth continues with 2026 projections of $26.3B, but profitability metrics need improvement for sustained shareholder value.
Novavax (NVAX) trades at $11.01, down 1.87% on the day, with a bullish technical signal from moving averages and a strong buy consensus from analysts (73.9% buy ratings). The company reported a net income of $440.3M in 2025, a significant turnaround from prior losses, though 2026 projections show a return to negative margins. Recent news highlights regulatory approvals for its COVID-19 vaccine and strategic pivots toward its Matrix-M adjuvant platform through partnerships.
The outlook is mixed: near-term catalysts include partnership-driven growth and vaccine approvals, but persistent cash burn and projected 2026 losses pose risks. Investor sentiment is buoyed by recent earnings beats and strategic shifts, yet execution on profitability remains critical for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Live Nation Entertainment, Inc.
Live Nation is the largest live entertainment firm in the world with over 570 million fans served in 44 countries in 2018 by the company's concert and ticketing platforms. Via either owning, operating, or holding exclusive booking rights, Live Nation controls over 235 venues including the House of Blues, the Hollywood Palladium, and Spark Arena in New Zealand. Live Nation also owns one of the largest ticketing services, Ticketmaster, which sold over 480 million tickets for over 12,000 clients in 2018. The firm's artist management agencies have over 400 clients. This large live entertainment footprint helped Live Nation become one of the largest advertising and sponsorship platforms aimed at music fans. Liberty Media owns 33% of Live Nation, held under its SiriusXM tracking stock.
Read more on LYV →About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →
